International Journal of Pharma Insight Studies

E-ISSN: 3107-393X
 

Full Journal Title: International Journal of Pharma Insight Studies
Abbreviation: IJPIS

Publication Body: Anfo Publication House
Editor in Chief: Dr. Barkat Ali Khan

Frequency of Publication: Bimonthly [6 issues per year]

Languages: English
License: CC BY-NC-SA 4.0
Open Access: Immediate Open Access
Similarity Screening Tool: Turnitin
Journal DOI: https://doi.org/10.54660/IJPIS
Website: www.pharmainsightstudies.com

 

About the Journal 

The International Journal of Pharma Insight Studies (IJPIS) is an international, peer-reviewed, open-access journal dedicated to publishing high-quality scholarly research in pharmaceutical sciences, pharmacology, pharmaceutics, clinical pharmacy, pharmaceutical chemistry, drug discovery, and related healthcare disciplines.

The journal provides a global platform for researchers, academicians, pharmacists, clinicians, healthcare professionals, pharmaceutical scientists, and industry experts to publish original research articles, systematic reviews, narrative reviews, clinical investigations, case reports, and evidence-based studies that contribute to scientific advancement and innovation in pharmaceutical and biomedical sciences.

IJPIS welcomes submissions from researchers worldwide and encourages interdisciplinary research addressing emerging pharmaceutical technologies, novel drug delivery systems, clinical therapeutics, pharmaceutical biotechnology, pharmacovigilance, regulatory sciences, and translational research aimed at improving patient care and public health.

The journal is committed to promoting scientific excellence, research integrity, innovation, and international collaboration by publishing high-quality manuscripts that contribute to the advancement of pharmaceutical education, research, and professional practice.

The International Journal of Pharma Insight Studies (IJPIS) is a fully open-access, peer-reviewed journal committed to the unrestricted dissemination of scientific knowledge. All published articles are made freely and immediately available online without subscription fees, registration requirements, or access restrictions.

Readers are permitted to read, download, copy, distribute, print, search, link to, and share the full text of published articles in accordance with the terms of the applicable Creative Commons license.

IJPIS supports the principles of the Budapest Open Access Initiative (BOAI) by promoting free and unrestricted access to scholarly research. The journal aims to enhance the global visibility, accessibility, and impact of scientific publications, enabling researchers, academicians, healthcare professionals, students, institutions, policymakers, and the wider scientific community to benefit from published research without financial barriers.

There is no embargo period. All accepted articles are published online and made immediately available in full text upon publication.

All articles published in the International Journal of Pharma Insight Studies (IJPIS) are licensed under the Creative Commons Attribution–NonCommercial–ShareAlike 4.0 International License (CC BY-NC-SA 4.0).

Under this license, users are permitted to:

1. Share: Copy and redistribute the published material in any medium or format.
2. Adapt: Remix, transform, and build upon the material for non-commercial purposes.
3. Attribute: Provide appropriate credit to the original author(s) and the International Journal of Pharma Insight Studies (IJPIS), include a link to the license, and indicate whether any changes were made.
4. ShareAlike: Distribute any modified or adapted material under the same CC BY-NC-SA 4.0 license.

Commercial use of published content is not permitted without prior written permission from the copyright holder(s).

Authors retain the copyright of their published work.

By submitting and publishing a manuscript in the International Journal of Pharma Insight Studies (IJPIS), authors grant the journal a non-exclusive license to publish, reproduce, distribute, archive, preserve, and make the article publicly available through electronic and other appropriate media.

Authors may share, distribute, archive, deposit in institutional repositories, and reuse their published articles, provided that appropriate acknowledgment is given to the original publication in the International Journal of Pharma Insight Studies (IJPIS).

The journal supports the long-term preservation and accessibility of published research while ensuring that authors retain ownership of their intellectual property under the terms of the applicable Creative Commons license.

Aims & Scope

The International Journal of Pharma Insight Studies (IJPIS) is an international, peer-reviewed, open-access journal dedicated to publishing high-quality research in pharmaceutical sciences, clinical pharmacy, pharmacology, and related healthcare disciplines. The journal serves as a platform for researchers, academicians, pharmacists, clinicians, healthcare professionals, and industry experts to disseminate original research, review articles, case reports, and scientific innovations that contribute to the advancement of pharmaceutical science, drug development, and patient care.

IJPIS welcomes multidisciplinary research that promotes scientific innovation, evidence-based practice, and translational research in pharmaceutical and biomedical sciences.

1. Pharmacology & Toxicology
2. Pharmaceutical Technology & Nanotechnology
3. Clinical & Hospital Pharmacy
4. Medicinal Chemistry & Biopharmaceutics
5. Pharmacogenomics & Drug Safety
6. Public Health and Regulatory Sciences

The International Journal of Pharma Insight Studies (IJPIS) follows the principles and guidance of the Committee on Publication Ethics (COPE) in addressing publication ethics, editorial integrity, complaints, appeals, corrections, retractions, and suspected research misconduct.

1. Peer Review: Each manuscript that passes the initial editorial screening is evaluated through a double-anonymous peer-review process by at least two independent reviewers with relevant subject expertise. The final editorial decision is made by the Editor-in-Chief or an assigned handling editor.
2. Plagiarism and Similarity Screening: All submitted manuscripts are screened using Turnitin or an equivalent similarity-checking tool. Similarity reports are assessed by the editorial team in context. Manuscripts found to contain plagiarism, duplicate publication, fabricated data, falsified information, manipulated citations, or other forms of research misconduct may be rejected or withdrawn in accordance with the journal's Publication Ethics and Malpractice Statement.
3. Transparency & Responsibility: Mandatory disclosure of conflicts of interest; clear editorial policies and Article Processing Charges (APCs).

For detailed policies, please visit the Publication Ethics and Malpractice Statement page.

International Journal of Pharma Insight Studies (IJPIS) maintains a strict zero-tolerance policy towards plagiarism. To ensure the highest standards of research integrity, every manuscript submitted to our journal undergoes a mandatory screening process:

1. Standard Screening: All submissions are rigorously checked for originality using Turnitin and iThenticate software.
2. Similarity Limit: We accept manuscripts with a similarity index of less than 15%. Any manuscript exceeding this limit is rejected or returned for revision.
3. Ethical Standards: We strictly prohibit direct copying, self-plagiarism, and improper paraphrasing.
4. Mandatory Requirement: Authors must ensure that all sources are accurately cited. Any violation of these ethical guidelines will lead to the immediate rejection of the manuscript.

1. Clear authorship criteria and contributor transparency.
2. Mandatory disclosure of conflicts of interest.
3. Ethical handling of research data, references, and citations.
4. Editorial independence, accountability, and fairness.

The International Journal of Pharma Insight Studies (IJPIS) is committed to maximizing the visibility and academic impact of published research. The journal is currently indexed and tracked in:

1. Google Scholar: Published articles may be discoverable through Google Scholar, subject to Google Scholar's indexing process and technical requirements.
2. Crossref DOI Registration: Digital Object Identifiers (DOIs) are registered through Crossref for articles to which a DOI is assigned, in accordance with the journal's DOI policy.
3. ROAD (Directory of Open Access Scholarly Resources): The journal is listed in ROAD, a directory managed by the ISSN International Centre for open-access scholarly resources.

The journal will update this page whenever it is accepted for inclusion in additional indexing and abstracting services.

The International Journal of Pharma Insight Studies (IJPIS) is a fully open-access journal. There is no submission fee and no peer-review fee.

An Article Processing Charge (APC) is payable only after a manuscript has successfully completed peer review and has been formally accepted for publication.

Publication Fee: USD 35 / INR 2,000 per accepted article.

The standard APC covers up to five authors. Additional charges may apply for manuscripts with more than five authors, as detailed in the Author Fees (APC) Policy.

The APC supports editorial handling, double-anonymous peer review, similarity screening, typesetting, online publication, digital archiving, and publication-related administrative services.

Authors should review the complete Author Fees (APC) Policy before submitting a manuscript.

The International Journal of Pharma Insight Studies (IJPIS) considers the following categories of manuscripts for peer review and publication:

1. Original Research Articles — Empirical studies reporting new experimental, clinical, or observational findings.
2. Systematic Reviews and Meta-Analyses — Comprehensive, methodologically rigorous syntheses of existing literature.
3. Narrative and Scoping Reviews — Broad, conceptually structured surveys of a research domain.
4. Clinical and Experimental Studies — Investigations involving pharmaceutical sciences, clinical pharmacy, pharmacology, and related biomedical research.
5. Case Reports and Case Series — Detailed documentation of clinically significant pharmaceutical and healthcare findings.
6. Short Communications — Concise reports of preliminary or rapidly emerging findings of scientific significance.
7. Letters to the Editor — Scholarly commentary on previously published articles or emerging scientific issues.

Authors may submit their manuscripts via email at [email protected] or through the online submission system: [Submit Manuscript]